Skip to main content

Clock Soon to Start Ticking on Myriad s 3-Year Proteome Effort

SAN FRANCISCO, Jan. 9 - Myriad Proteomics in mid-January will begin trying to fulfill its pledge to map the human proteome within three years as researchers get set to move into the company's new facility, Peter Meldrum, CEO of Myriad Genetics, said on Wednesday.


Move-in day, Jan. 16, is when the three-year time clock starts ticking.


In April, Myriad joined with Hitachi and Oracle to start Myriad Proteomics. Since that time, Myriad Proteomics has designed, built, and furnished its facility Salt Lake City and hired a 50-person staff, Meldrum said. He spoke at the 20th annual JPMorgan H&Q Healthcare Conference here, which ends on Thursday.


Myriad Genetics has 50 percent ownership in the proteomics venture. "They will map the human proteome and we will get free access to the data," said Meldrum.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.